Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)

#3206

Introduction: The kidney is a dose-limiting organ in PRRT. Most clinical studies have focused on the safety of PRRT with normal or mildly impaired kidney function.

Aim(s): The aim of this study is to assess the efficacy and safety of 177-Lu DOTATATE in patients with NETs with eGFR between (30-60).

Materials and methods: A retrospective analysis of 55 patients with eGFR<60 (range 33-59). 29 females and 26 males. mean age 67 ±11 year. 44 patients with chronic kidney disease (CKD) stage 3a (eGFR between 45-60) and 11 with CKD 3b (eGFR between 30-45). The mean follow-up period was 35 months (range 12-79 months). Survival analysis was performed using Kaplan-Meier method. Response was evaluated using CT or MRI and according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Toxicity was defined using Common Terminology Criteria for Adverse Events version 5 (CTCAE 5.0).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, chronic kidney disease,